Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734694 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT01734694 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 100 participants.
The verdict
NCT01734694, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
Interventions
- DRUG Vancomycin
- DRUG Ceftaroline
- DRUG Linezolid
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01734694
The ClinicalTrials.gov registry entry for NCT01734694 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vancomycin is the first listed.
NCT01734694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01734694 about?
NCT01734694 is a clinical study titled "Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients". For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due...
What is the current status of trial NCT01734694?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2011-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01734694?
The interventions under investigation include: Vancomycin (DRUG), Ceftaroline (DRUG), Linezolid (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT01734694?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.